JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Literature - Publication Review
Developing a phenotypic in vitro model for progression of liver steatosis
Currently, there are no FDA-approved medicines to treat nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), and the complex molecular and genetic mechanisms are not completely understood. To address this, Siobhan Malany, from the Conrad Prebys Center for Chemical Genomics in Florida, US, and colleagues developed a model of hepatic steatosis in functional human induced pluripotent stem cell-derived hepatocytes (hiPSC-Hep). This article discusses some of the study’s main approaches, findings, and potential applications for drug discovery research.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Developing a phenotypic in vitro model for progression of liver steatosis